Home / Market News / $SBFM
benzinga Corporate Catalyst Impact 55/100 ● positive

Sunshine Biopharma Announces Approval Of Atenolol Tablets Of 25mg, 50mg And 100mg For Canadian Market

Aug 31, 2026, 1:03 PM UTC · Primary ticker $SBFM

Sunshine Biopharma announced Health Canada approval for its generic Atenolol tablets (25mg, 50mg, 100mg). This approval allows the company to market and sell these beta-blocker medications in Canada, representing a new revenue stream and market expansion opportunity.

Sunshine Biopharma has secured Health Canada approval for its generic Atenolol tablets. This is a positive development as it allows SBFM to enter the Canadian market with a well-established medication used for hypertension and other cardiovascular conditions. While not a groundbreaking drug, it represents a new revenue stream and expands the company's product portfolio and geographic reach. The short-term impact might be moderate as generic drug launches typically have a gradual ramp-up, but it signifies progress in the company's commercialization efforts and could contribute to long-term growth and stability.

$SBFM positive Product approval and market expansion
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.